Table 2:
Hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between tumor-associated stromal cellular density (SCD) and clinical outcomes in breast cancer patients from three independent study populations, overall and stratified by hormone receptor-expression
| Study population | ||||||
|---|---|---|---|---|---|---|
| CHCAMS | PBCS | PLCO | Meta-analysis | |||
| SCD categories | HR (95% CI)ϯ | HR (95% CI)ф | HR (95% CI) ф | HR (95% CI) | P het | |
| Univariable | ||||||
| All subjects | ||||||
| Q1 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | |||
| Q2 | 1.17 (0.78, 1.74) | 1.21 (0.73, 2.00) | 1.18 (0.80, 1.57) | |||
| Q3 | 1.43 (0.98, 2.09) | 1.22 (0.74, 2.01) | 1.34 (0.92, 1.76) | |||
| Q4 | 1.60 (1.09, 2.32) | 2.52 (1.60, 3.95) | 1.93 (1.07, 2.80) | |||
| Trend | 1.17 (1.04, 1.32) | 1.36 (1.17, 1.57) | 1.25 (1.07, 1.44) | 0.13 | ||
| P trend | 0.007 | <0.001 | ||||
| Continuous, per 10% | 1.14 (0.98, 1.29) | 1.31 (1.16, 1.45) | 1.23 (1.06, 1.39) | |||
| P value | 0.08 | <0.001 | ||||
| HR+ (luminal) | ||||||
| Q1 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | ||
| Q2 | 1.08 (0.61, 1.92) | 1.31 (0.80, 2.14) | 1.15 (0.60, 2.22) | 1.18 (0.78, 1.58) | ||
| Q3 | 0.66 (0.34, 1.24) | 1.64 (1.03, 2.62) | 1.53 (0.83, 2.83) | 1.19 (0.50, 1.87) | ||
| Q4 | 2.03 (1.22, 3.39) | 2.21 (1.40, 3.47) | 3.14 (1.77, 5.57) | 2.26 (1.56, 2.96) | ||
| Trend | 1.24 (1.04, 1.48) | 1.30 (1.13, 1.49) | 1.50 (1.24, 1.81) | 1.32 (1.19, 1.44) | 0.35 | |
| P trend | 0.02 | <0.001 | <0.001 | |||
| Continuous, per 10% | 1.32 (1.05, 1.59) | 1.26 (1.05, 1.47) | 1.40 (1.23, 1.57) | 1.34 (1.22, 1.46) | ||
| P value | 0.02 | 0.01 | <0.001 | |||
| HR− (non-luminal) | ||||||
| Q1 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | |||
| Q2 | 1.70 (0.83, 3.46) | 0.42 (0.16, 1.10) | 0.91 (0.31, 2.12) | |||
| Q3 | 0.78 (0.36, 1.71) | 0.69 (0.30, 1.54) | 0.73 (0.27, 1.19) | |||
| Q4 | 1.03 (0.47, 2.26) | 0.74 (0.30, 1.81) | 0.86 (0.28, 1.44) | |||
| Trend | 0.92 (0.73, 1.17) | 0.92 (0.67, 1.24) | 0.92 (0.75, 1.09) | 1.00 | ||
| P trend | 0.52 | 0.56 | ||||
| Continuous, per 10% | 0.91 (0.60, 1.23) | 0.98 (0.69, 1.27) | 0.95 (0.73, 1.16 | |||
| P value | 0.58 | 0.91 | ||||
| Multivariable | ||||||
| All subjects | ||||||
| Q1 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | |||
| Q2 | 1.19 (0.80, 1.78) | 1.11 (0.66, 1.85) | 1.16 (0.78, 1.54) | |||
| Q3 | 1.21 (0.82, 1.78) | 1.08 (0.65, 1.81) | 1.16 (0.78, 1.53) | |||
| Q4 | 1.26 (0.86, 1.85) | 1.84 (1.13, 3.00) | 1.41 (0.91, 1.91) | |||
| Trend | 1.07 (0.95, 1.20) | 1.22 (1.04, 1.43) | 1.13 (0.98, 1.27) | 0.21 | ||
| P trend | 0.27 | 0.01 | ||||
| Continuous, per 10% | 0.99 (0.83, 1.15) | 1.18 (1.02, 1.34) | 1.08 (0.90, 1.27) | |||
| P value | 0.88 | 0.02 | ||||
| HR+ (luminal) | ||||||
| Q1 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | ||
| Q2 | 0.87 (0.46, 1.64) | 1.29 (0.79, 2.11) | 1.06 (0.55, 2.05) | 1.06 (0.55, 2.05) | ||
| Q3 | 0.54 (0.26, 1.10) | 1.38 (0.85, 2.21) | 1.35 (0.73, 2.52) | 1.01 (0.41, 2.25) | ||
| Q4 | 1.86 (1.06, 3.26) | 1.80 (1.12, 2.89) | 2.42 (1.33, 4.42) | 1.92 (1.29, 2.55) | ||
| Trend | 1.24 (1.02, 1.51) | 1.20 (1.04, 1.39) | 1.37 (1.13, 1.67) | 1.25 (1.10, 1.37) | 0.58 | |
| P trend | 0.03 | 0.01 | 0.002 | |||
| Continuous, per 10% | 1.31 (1.02, 1.62) | 1.14 (0.92, 1.36) | 1.31 (1.12, 1.51) | 1.25 (1.12, 1.38) | ||
| P value | 0.03 | 0.20 | 0.001 | |||
| HR− (non-luminal) | ||||||
| Q1 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | |||
| Q2 | 2.21 (0.99, 4.92) | 0.34 (0.11, 1.00) | 1.02 (0.74, 2.78) | |||
| Q3 | 1.32 (0.58, 3.00) | 0.39 (0.15, 1.03) | 0.68 (0.16, 1.52) | |||
| Q4 | 1.06 (0.46, 2.45) | 0.42 (0.14, 1.29) | 0.61 (0.04, 1.18) | |||
| Trend | 0.95 (0.75, 1.20) | 0.70 (0.48, 1.02) | 0.84 (0.59, 1.08) | 0.16 | ||
| P trend | 0.65 | 0.07 | ||||
| Continuous, per 10% | 0.94 (0.64, 1.24) | 0.77 (0.43, 1.12) | 0.87 (0.64, 1.09) | |||
| P value | 0.69 | 0.20 | ||||
Hazard ratios (HRs) and 95% confidence intervals (CIs) were obtained from Cox proportional hazard regression models. Univariable HRs were adjusted for age and total tissue area while multivariable models had additional adjustments for histologic grade, tumor size, lymph nodal involvement, subtype, and systematic treatment (endocrine therapy, and/or trastuzumab, or adjuvant chemotherapy). Meta-analysis of HR estimates was performed using the random effects modeling approach. Breast cancer patients from the Cancer Hospital Chinese Academy of Medical Sciences (CHCAMS) were premenopausal women, aged 24-55 years, with hormone receptor-positive (HR+ (luminal)) breast cancer, while those from the Prostate, Lung, Colorectal and Ovarian cancer (PLCO) screening trial were postmenopausal women, aged 55-87 years, unselected for hormone receptor-status. Polish breast cancer patients from the Polish Breast Cancer Study (PLCO) were aged 31-75 years and unselected for menopausal status.
10-year disease-free survival (DFS).
10-year overall survival (OS).